Wilbanks Smith & Thomas Asset Management’s AstraZeneca AZN Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$427K	Buy	+3,151	New	+$417K	0.01%	369
2023 Q4	–	Sell	-1,480	Closed	-$200K	–	520
2023 Q3	$200K	Sell	1,480 -53	-3%	-$7.24K	0.01%	481
2023 Q2	$219K	Sell	1,533 -72	-4%	-$10.6K	0.01%	477
2023 Q1	$223K	Sell	1,605 -22	-1%	-$2.96K	0.01%	469
2022 Q4	$221K	Sell	1,627 -375	-19%	-$47K	0.01%	458
2022 Q3	$220K	Buy	2,002 +160	+9%	+$20.3K	0.01%	423
2022 Q2	$243K	Sell	1,842 -31	-2%	-$4.07K	0.01%	417
2022 Q1	$252K	Sell	1,873 -84	-4%	-$10.1K	0.01%	431
2021 Q4	$228K	Sell	1,957 -18	-0.9%	-$2.12K	0.01%	469
2021 Q3	$237K	Buy	+1,975	New	+$230K	0.01%	444
2018 Q4	–	Sell	-461	Closed	-$36K	–	433
2018 Q3	$36K	Buy	+461	New	+$34.9K	﹤0.01%	749

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's AZN Position: Q1 2024 in Review

Wilbanks Smith & Thomas Asset Management opened a new position in AstraZeneca (AZN) in Q1 2024: 3,151 shares worth $427K. The stake represents 0.01% of the portfolio and ranks #369 among its holdings. This is a return to the name: Wilbanks Smith & Thomas Asset Management previously reported a position in AZN as recently as Q3 2023.

Wilbanks Smith & Thomas Asset Management first reported a position in AZN in Q3 2018 and has held it in 11 quarters since. 1,142 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

Wilbanks Smith & Thomas Asset Management held 3,151 shares of AstraZeneca worth $427K as of Q1 2024.
AstraZeneca was a new Wilbanks Smith & Thomas Asset Management position in Q1 2024.
AstraZeneca made up 0.01% of Wilbanks Smith & Thomas Asset Management's portfolio in Q1 2024, its #369 holding.
Wilbanks Smith & Thomas Asset Management first reported a position in AstraZeneca in Q3 2018 and has held it in 11 quarters since.
1,142 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q1 2024, filed 7 May 2024.